The Netherlands health authority warns on falsified tirzepatide pens
Reported from the analysis, not from a warning notice.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 5 of 5 of this archive, newest first.
Reported from the analysis, not from a warning notice.
The observation that closes a facility is rarely the dramatic one.
The evidence base is thin and the document says so, which is to its credit.
The purity figure is the least informative line on a well-constructed certificate and the only line most buyers read.
The features that should prompt urgent assessment, stated once and plainly.
Reducing a dose is not going backwards. In a tolerability-limited class it is the mechanism by which the ceiling is found.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Efficacy was never the question in this appraisal. Duration of treatment was.
A proper account of an operation that existed, and of what closing it cost.
The document is four pages. Three of them are about dates.